Roivant Sciences is trading 4.1% down at $34.51 as the broader biotech sector pulls back and investors take profits following a sharp rally.
- The decline follows a strong multi-week run supported by deal-related cash inflows, bullish analyst coverage, and index-driven buying.
- There is no new company-specific negative catalyst today; the move appears to be normal consolidation and sector-wide pressure on high-beta names.